Evidence that GRIN2A mutations in melanoma correlate with decreased survival
Previous whole-exome sequencing has demonstrated that melanoma tumours harbour mutations in the GRIN2A gene. GRIN2A encodes the regulatory GluN2A subunit of the glutamate-gated N-methyl-D-aspartate receptor (NMDAR), involvement of which in melanoma remains undefined. Here, we sequenced coding exons...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2014-01-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2013.00333/full |
id |
doaj-8a3ae31fdd5a48a9852a42d671db39be |
---|---|
record_format |
Article |
spelling |
doaj-8a3ae31fdd5a48a9852a42d671db39be2020-11-24T22:35:55ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2014-01-01310.3389/fonc.2013.0033374132Evidence that GRIN2A mutations in melanoma correlate with decreased survivalStacey Ann N D'mello0Jack U Flanagan1Jack U Flanagan2Taryn N Green3Euphemia Y Leung4Marjan E Askarian-Amiri5Wayne R Joseph6Michael R McCrystal7Michael R McCrystal8Richard J Isaacs9James H F Shaw10Christopher E Furneaux11Matthew J During12Matthew J During13Graeme J FInlay14Bruce C Baguley15Maggie Lucy Kalev-Zylinska16Maggie Lucy Kalev-Zylinska17University of AucklandUniversity of AucklandUniversity of AucklandUniversity of AucklandUniversity of AucklandUniversity of AucklandUniversity of AucklandAuckland District Health BoardMercy HospitalPalmerston North Public HospitalOncology Surgery LtdAuckland District Health BoardOhio State UniversityUniversity of AucklandUniversity of AucklandUniversity of AucklandUniversity of AucklandAuckland District Health BoardPrevious whole-exome sequencing has demonstrated that melanoma tumours harbour mutations in the GRIN2A gene. GRIN2A encodes the regulatory GluN2A subunit of the glutamate-gated N-methyl-D-aspartate receptor (NMDAR), involvement of which in melanoma remains undefined. Here, we sequenced coding exons of GRIN2A in 19 low-passage melanoma cell lines derived from patients with metastatic melanoma. Potential mutation impact was evaluated in silico, including within the GluN2A crystal structure, and clinical correlations were sought. We found that of 19 metastatic melanoma tumours, four (21%) carried five missense mutations in the evolutionarily conserved domains of GRIN2A; two were previously reported. Melanoma cells that carried these mutations were treatment-naïve. SIFT analysis predicted that S349F, G762E and P1132L would disrupt protein function. When modelled into the crystal structure of GluN2A, G762E was seen to potentially alter GluN1-GluN2A interactions and ligand binding, implying disruption to NMDAR functionality. Patients whose tumours carried nonsynonymous GRIN2A mutations had faster disease progression and shorter overall survival (P < 0.05). This was in contrast to the BRAF V600E mutation, found in 58% of tumours but showing no correlation with clinical outcome (P = 0.963). Although numbers of patients in this study are small, and firm conclusions about the association between GRIN2A mutations and poor clinical outcome cannot be drawn, our results highlight the high prevalence of GRIN2A mutations in metastatic melanoma and suggest for the first time that mutated NMDARs impact melanoma progression.http://journal.frontiersin.org/Journal/10.3389/fonc.2013.00333/fullMelanomaMutationGlutamatebiomarkerprognosisNMDA receptor |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Stacey Ann N D'mello Jack U Flanagan Jack U Flanagan Taryn N Green Euphemia Y Leung Marjan E Askarian-Amiri Wayne R Joseph Michael R McCrystal Michael R McCrystal Richard J Isaacs James H F Shaw Christopher E Furneaux Matthew J During Matthew J During Graeme J FInlay Bruce C Baguley Maggie Lucy Kalev-Zylinska Maggie Lucy Kalev-Zylinska |
spellingShingle |
Stacey Ann N D'mello Jack U Flanagan Jack U Flanagan Taryn N Green Euphemia Y Leung Marjan E Askarian-Amiri Wayne R Joseph Michael R McCrystal Michael R McCrystal Richard J Isaacs James H F Shaw Christopher E Furneaux Matthew J During Matthew J During Graeme J FInlay Bruce C Baguley Maggie Lucy Kalev-Zylinska Maggie Lucy Kalev-Zylinska Evidence that GRIN2A mutations in melanoma correlate with decreased survival Frontiers in Oncology Melanoma Mutation Glutamate biomarker prognosis NMDA receptor |
author_facet |
Stacey Ann N D'mello Jack U Flanagan Jack U Flanagan Taryn N Green Euphemia Y Leung Marjan E Askarian-Amiri Wayne R Joseph Michael R McCrystal Michael R McCrystal Richard J Isaacs James H F Shaw Christopher E Furneaux Matthew J During Matthew J During Graeme J FInlay Bruce C Baguley Maggie Lucy Kalev-Zylinska Maggie Lucy Kalev-Zylinska |
author_sort |
Stacey Ann N D'mello |
title |
Evidence that GRIN2A mutations in melanoma correlate with decreased survival |
title_short |
Evidence that GRIN2A mutations in melanoma correlate with decreased survival |
title_full |
Evidence that GRIN2A mutations in melanoma correlate with decreased survival |
title_fullStr |
Evidence that GRIN2A mutations in melanoma correlate with decreased survival |
title_full_unstemmed |
Evidence that GRIN2A mutations in melanoma correlate with decreased survival |
title_sort |
evidence that grin2a mutations in melanoma correlate with decreased survival |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2014-01-01 |
description |
Previous whole-exome sequencing has demonstrated that melanoma tumours harbour mutations in the GRIN2A gene. GRIN2A encodes the regulatory GluN2A subunit of the glutamate-gated N-methyl-D-aspartate receptor (NMDAR), involvement of which in melanoma remains undefined. Here, we sequenced coding exons of GRIN2A in 19 low-passage melanoma cell lines derived from patients with metastatic melanoma. Potential mutation impact was evaluated in silico, including within the GluN2A crystal structure, and clinical correlations were sought. We found that of 19 metastatic melanoma tumours, four (21%) carried five missense mutations in the evolutionarily conserved domains of GRIN2A; two were previously reported. Melanoma cells that carried these mutations were treatment-naïve. SIFT analysis predicted that S349F, G762E and P1132L would disrupt protein function. When modelled into the crystal structure of GluN2A, G762E was seen to potentially alter GluN1-GluN2A interactions and ligand binding, implying disruption to NMDAR functionality. Patients whose tumours carried nonsynonymous GRIN2A mutations had faster disease progression and shorter overall survival (P < 0.05). This was in contrast to the BRAF V600E mutation, found in 58% of tumours but showing no correlation with clinical outcome (P = 0.963). Although numbers of patients in this study are small, and firm conclusions about the association between GRIN2A mutations and poor clinical outcome cannot be drawn, our results highlight the high prevalence of GRIN2A mutations in metastatic melanoma and suggest for the first time that mutated NMDARs impact melanoma progression. |
topic |
Melanoma Mutation Glutamate biomarker prognosis NMDA receptor |
url |
http://journal.frontiersin.org/Journal/10.3389/fonc.2013.00333/full |
work_keys_str_mv |
AT staceyannndmello evidencethatgrin2amutationsinmelanomacorrelatewithdecreasedsurvival AT jackuflanagan evidencethatgrin2amutationsinmelanomacorrelatewithdecreasedsurvival AT jackuflanagan evidencethatgrin2amutationsinmelanomacorrelatewithdecreasedsurvival AT tarynngreen evidencethatgrin2amutationsinmelanomacorrelatewithdecreasedsurvival AT euphemiayleung evidencethatgrin2amutationsinmelanomacorrelatewithdecreasedsurvival AT marjaneaskarianamiri evidencethatgrin2amutationsinmelanomacorrelatewithdecreasedsurvival AT waynerjoseph evidencethatgrin2amutationsinmelanomacorrelatewithdecreasedsurvival AT michaelrmccrystal evidencethatgrin2amutationsinmelanomacorrelatewithdecreasedsurvival AT michaelrmccrystal evidencethatgrin2amutationsinmelanomacorrelatewithdecreasedsurvival AT richardjisaacs evidencethatgrin2amutationsinmelanomacorrelatewithdecreasedsurvival AT jameshfshaw evidencethatgrin2amutationsinmelanomacorrelatewithdecreasedsurvival AT christopherefurneaux evidencethatgrin2amutationsinmelanomacorrelatewithdecreasedsurvival AT matthewjduring evidencethatgrin2amutationsinmelanomacorrelatewithdecreasedsurvival AT matthewjduring evidencethatgrin2amutationsinmelanomacorrelatewithdecreasedsurvival AT graemejfinlay evidencethatgrin2amutationsinmelanomacorrelatewithdecreasedsurvival AT brucecbaguley evidencethatgrin2amutationsinmelanomacorrelatewithdecreasedsurvival AT maggielucykalevzylinska evidencethatgrin2amutationsinmelanomacorrelatewithdecreasedsurvival AT maggielucykalevzylinska evidencethatgrin2amutationsinmelanomacorrelatewithdecreasedsurvival |
_version_ |
1725722237649027072 |